Replies to post #182628 on Biotech Values

[DewDiligence]

MNTA—M923 (Humira) phase-1 to start by year-end 2014. (Source: today’s R&D Day webcast)

[tony111]

That means m402 with gem and ab combo need to produce an median OS of 12 months!!! Thats a very high hurdle.

[DewDiligence]

MNTA’s Necuparanib receives FDA Fast Track designation for pancreatic cancer:

http://finance.yahoo.com/news/momenta-pharmaceuticals-necuparanib-receives-fast-131500946.html

Necuparanib also has an FDA Orphan Drug indication for the same indication (#msg-102765888). The phase-1 data from the ongoing phase-1/2 trial testing Gemzar+Abraxane ± Necuparanib were reported in detail at MNTA’s R&D Day in October (#msg-107057169).